Transcription Factor May Protect Against Hepatic Injury Caused by Hepatitis C and Alcohol

More damage seen when FOXO3 suppressed, according to report in The American Journal of Pathology

Philadelphia, PA, November 11, 2013

New data suggest that the transcription factor FOXO3 may protect against alcohol-induced liver injury. Researchers determined that alcohol given to mice deficient in FOXO3 caused severe liver injury resembling human alcoholic hepatitis. Further they found that although hepatitis C virus (HCV) and alcohol independently activated FOXO3, in combination they suppressed FOXO3, reduced expression of cytoprotective genes, and worsened liver injury. The results are published in The American Journal of Pathology.

"There is emerging evidence that the FOXO transcription factor family plays a critical role in metabolic, antioxidant, and cell death responses in the liver. The role of FOXO in injury processes is complex as FOXO transcription programs can either be cytoprotective or cytotoxic, and well-documented examples of both phenomena are numerous," says Steven A. Weinman, MD, PhD, Department of Internal Medicine at the University of Kansas Medical Center.

Based on such emerging evidence, Dr. Weinman's group fed alcohol to FOXO3-deficient mice for three weeks. One third of these mice developed severe hepatic steatosis (infiltration of liver cells with fat), neutrophil infiltration, and necrosis, similar to that seen in patients with alcoholic hepatitis. In some mice, levels of the liver enzyme alanine aminotransferase (ALT) increased tenfold compared to controls.

Investigators also induced severe liver injury with alcohol in a mouse model of HCV (transgenic HCV/Sod2+/-). These animals had elevated ALT; increased ICAM-1 expression and caspase 3 cleavage, and severe steatosis, lobular inflammation, and ballooning degeneration of liver cells. In these mice, degree of liver injury correlated with levels of the mitochondrial antioxidant enzyme superoxide dismutase (SOD2). (SOD2 is also thought to play a part in protecting the liver from alcoholic injury.) Alcohol-treated HCV/Sod2+/- mice also showed a greater concentration of FOXO3 in the cytosol of the cell compared to the nuclear location found in other types of mice.

Weinman continues, "One of the important unanswered questions about alcoholic liver disease has been why only a minority of those who drink, including those who drink heavily, ever develop liver disease. In most people, the liver has efficient protection mechanisms against alcohol. Our results indicate that FOXO3 is a novel alcohol protection factor that is disrupted by the HCV-alcohol combination. We therefore think that modulation of the FOXO3 pathway is a potential therapeutic approach for HCV-alcohol-induced liver injury."

In cell culture, either HCV or alcohol alone produced an increase in FOXO3 transcriptional activity. However, Weinman and colleagues found that although the effects of both of these stress stimuli on FOXO3 were similar, the mechanisms of action were different. For example, although HCV activation was associated with translocation of FOXO3 from cytosol to the nucleus, alcohol produced transcriptional activation without a prominent change in the nuclear-cytosolic ratio. Another difference found was that HCV, but not alcohol, caused a miRNA-dependent suppression of SOD2 translation.

That HCV infection and alcohol exposure appear to work in synergy to produce effects that are different from those seen with either alone was a "novel and unexpected" finding, says Weinman. The suppression of FOXO3 by the combination of HCV and alcohol is attributed in part to nuclear export and a decreased protein half-life that does not occur with either HCV or alcohol alone. "The results indicate that FOXO3 is a novel alcohol protection factor that is disrupted by the HCV-alcohol combination," concludes Weinman.

In the same issue of The American Journal of Pathology, another team of investigators from the University of Kansas Medical Center, led by Dr. Wen-Xing Ding, PhD, Department of Pharmacology, Toxicology, and Therapeutics, also report that FOXO3 protects against acute ethanol-induced steatosis and liver injury. This study demonstrates that FOXO3 is necessary for activation of autophagy, a cellular degradation pathway that protects against alcohol-induced liver injury by removing damaged mitochondria. Acute alcohol-treated FOXO3-deficient mice developed more severe liver injury than that of wild-type mice, and this was attributed to decreased expression of autophagy-related genes.

"Our study," says Dr. Ding, "was an acute alcohol model whereas the study in Dr. Weinman's laboratory was a chronic alcohol feeding model; however, both studies show that FOXO3 is protective. Thus, these results indicate that FOXO3 is an important general mechanism by activating multiple cellular protective functions that the normal liver uses to resist the toxic effects of alcohol."


# # #


Notes for editors

"Hepatitis C and Alcohol Exacerbate Liver Injury by Suppression of FOXO3," by Batbayar Tumurbaatar, Irina Tikhanovich, Zhuan Li, Jinyu Ren, Robert Ralston, Sudhakiranmayi Kuravi, Roosevelt Campbell, Gaurav Chaturvedi, Ting-Ting Huang, Jie Zhao, Junfang Hao, Maura O'Neil, and Steven A. Weinman (DOI: http://dx.doi.org/10.1016/j.ajpath.2013.08.013).

"Critical Role of FoxO3a in Alcohol-Induced Autophagy and Hepatotoxicity," by Hong-Min Ni, Kuo Du, Min You, and Wen-Xing Ding (DOI: http://dx.doi.org/10.1016/j.ajpath.2013.08.011).

They appear in The American Journal of Pathology, Volume 183, Issue 6 (December 2013) published by Elsevier.

Full text of the articles is available to credentialed journalists upon request; contact Eileen Leahy at +1 732 238 3628 or ajpmedia@elsevier.com. Journalists wishing to interview Steven A. Weinman may contact him at +1 913 945 6945 or sweinman@kumc.edu. To interview Wen-Xing Ding contact him at +1 913 588 9813 or wxding@kumc.edu.

About The American Journal of Pathology
The American Journal of Pathology (http://ajp.amjpathol.org), official journal of the American Society for Investigative Pathology, seeks to publish high-quality, original papers on the cellular and molecular biology of disease. The editors accept manuscripts that advance basic and translational knowledge of the pathogenesis, classification, diagnosis, and mechanisms of disease, without preference for a specific analytic method. High priority is given to studies on human disease and relevant experimental models using cellular, molecular, animal, biological, chemical, and immunological approaches in conjunction with morphology.

The leading global forum for reporting quality original research on cellular and molecular mechanisms of disease, The American Journal of Pathology is the most highly cited journal in Pathology – over 38,000 cites in 2012 – with an Impact Factor of 4.522 and Eigenfactor of 0.07599 according to the 2012 Journal Citation Reports®, Thomson Reuters, and an h-index of 181 according to the 2011 SCImago Journal and Country Rank.

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact
Eileen Leahy
Elsevier
+1 732 238 3628
ajpmedia@elsevier.com


Dr. Chhavi Chauhan
Scientific Editor
The American Journal of Pathology

+1 301 634 7953
cchauhan@asip.org